This review examines current and emerging therapies for lower-risk MDS, including drugs that improve red blood cell production (luspatercept, erythropoietin), drugs targeting genetic abnormalities (lenalidomide), and promising new agents that may slow disease progression. Here, EPO is linked to myelodysplastic syndrome.